Dominic Reynolds BA, MA, PhD

Dominic Reynolds, Ph.D., joined H3 Biomedicine in 2011 and has held positions of increasing scientific and management responsibility. Currently, as, Executive Director of Chemistry he leads a team of chemists towards identification and development of novel, small molecule oncology therapeutics.
For each project, Dominic and his team of chemists establishes mutually agreeable research plans and timelines, coordinates resources across multiple sites and time zones, mediates and resolves conflicts, and collaborates with internal and external leadership to gain support for critical project needs. Under his leadership, Dominic’s team has delivered a pre-clinical candidate in a highly competitive area of oncology by employing a de-novo design strategy. The molecule is currently undergoing GLP toxicity assessment.
Dominic joined H3 from Forma Therapeutics where in addition to Medicinal Chemistry project leadership he was heavily involved in scientific collaborations targeting over 100,000 novel, stereochemically- complex, small molecules according to the principles of Diversity Oriented Synthesis.
Prior to Forma, Dominic worked at Millennium Pharmaceuticals, Cambridge, MA where he was involved in select oncology research and development projects from lead discovery to candidate delivery for multiple target classes. Dominic also served as a post-doctoral researcher at Glaxo Welcome, UK as well as Harvard University with Professor David Evans; Dominic earned his Ph.D. with Professor Steven Ley, and a B.A. in natural sciences both at the University of Cambridge.